The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer

被引：0
|
作者：
Oikawa, Masahiro
Ishida, Mayumi
Nakamura, Yoshiaki
Nishimura, Sumiko
Koga, Chinami
Saruwatari, Akihiro
Igawa, Akiko
Akiyoshi, Sayuri
Koi, Yumiko
Ohno, Shinji
机构：
[1] Kyushu Natl Canc Ctr, Dept Breast Oncol, Fukuoka, Japan
[2] Kyushu Natl Canc Ctr, Dept Clin Oncol, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
563
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    [J]. ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
  • [2] Elacestrant in advanced ER-positive, HER2-negative breast cancer
    Kuenzell, Judith Lorenz
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 16 - 16
  • [3] Clinical implications of molecular heterogeneity in highly proliferative, ER-positive, HER2-negative breast cancer
    Bianchini, G.
    Pusztai, L.
    Kelly, C. M.
    Iwamoto, T.
    Callari, M.
    Symmans, W. F.
    Gianni, L.
    [J]. CANCER RESEARCH, 2012, 72
  • [4] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D. Hart
    Ilenia Migliaccio
    Luca Malorni
    Cristina Guarducci
    Laura Biganzoli
    Angelo Di Leo
    [J]. Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
  • [5] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
    Abraham, Jame
    Mechcatie, Elizabeth
    [J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86
  • [6] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Hart, Christopher D.
    Migliaccio, Ilenia
    Malorni, Luca
    Guarducci, Cristina
    Biganzoli, Laura
    Di Leo, Angelo
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (09) : 541 - 552
  • [7] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    [J]. CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [8] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [9] Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
    Matikas, Alexios
    Foukakis, Theodoros
    Michalakis, Ilias
    Georgoulias, Vassilis
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 319 - 326
  • [10] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
12345